FDA Refuses to File Moderna mRNA Flu Vaccine Application Over Trial Comparator Dispute
The FDA’s CBER issued a refusal‑to‑file for Moderna’s investigational mRNA seasonal influenza vaccine, saying the Phase 3 trial was not “adequate and well‑controlled” because Moderna used a licensed standard‑dose comparator rather than the higher‑dose “best‑available” standard of care for older adults; Moderna says the agency did not object to the protocol when it was submitted in April 2024 or before the trial began in September 2024 and that 2024 guidance had indicated a standard‑dose comparator could be acceptable. A pre‑submission meeting in August 2025 flagged the comparator as a “significant issue” without warning of a possible refusal, and commentators have placed the decision in the broader context of recent vaccine‑policy changes at HHS, including removal of VRBPAC members, canceled mRNA vaccine contracts, narrowed COVID authorizations and removal of COVID shots from some immunization schedules.
📌 Key Facts
- CBER issued a refusal-to-file letter for Moderna’s mRNA flu vaccine application, saying the Phase 3 study was not “adequate and well-controlled” because Moderna used a licensed standard‑dose flu vaccine comparator rather than what the FDA calls the “best‑available standard of care” (a higher‑dose vaccine for older adults).
- Moderna says the FDA did not object to the Phase 3 protocol when it was submitted in April 2024 or before the trial began in September 2024, and notes that 2024 FDA guidance indicated a standard‑dose comparator would be acceptable while recommending a higher‑dose comparator for people 65 and older.
- A pre‑submission meeting in August 2025 identified the comparator choice as a “significant issue” for review but, according to reports, did not warn Moderna that the entire application might be refused.
- The refusal centers on a procedural dispute over the trial comparator (standard‑dose vs. higher‑dose for seniors) and whether that choice meets FDA’s adequacy standards for an "adequate and well‑controlled" study.
- The decision comes amid broader vaccine policy changes under HHS Secretary Robert F. Kennedy Jr., including removal of members from the Vaccines and Related Biological Products Advisory Committee (VRBPAC), cancellation of about $500 million in mRNA vaccine contracts, narrowing COVID‑19 vaccine authorization to high‑risk groups, and removing COVID shots from childhood and pregnancy immunization schedules.
📊 Analysis & Commentary (1)
"The Wall Street Journal editorial attacks FDA vaccine chief Vinay Prasad for the agency’s refusal‑to‑file Moderna’s mRNA flu vaccine application, calling the move arbitrary, harmful to innovation and unjustified given prior communications about the trial protocol."
📰 Source Timeline (2)
Follow how coverage of this story developed over time
- Confirms CBER’s refusal-to-file letter cites lack of an 'adequate and well-controlled' study because Moderna used a licensed standard-dose flu vaccine comparator rather than what FDA calls the 'best-available standard of care' (higher‑dose vaccine for older adults).
- Reports Moderna’s claim that FDA did not previously object to the Phase 3 protocol when submitted in April 2024 or before the trial began in September 2024, and that 2024 FDA guidance had said a standard-dose comparator would be acceptable though a higher-dose was recommended for 65+.
- Details that a pre-submission meeting in August 2025 flagged the comparator as a 'significant issue' for review but did not warn Moderna that the entire application might be refused.
- Places the decision squarely in the context of RFK Jr.’s vaccine policy changes: removal of VRBPAC members, cancellation of about $500 million in mRNA vaccine contracts, narrowing COVID vaccine authorization to high‑risk groups, and removing COVID shots from the childhood and pregnancy schedules.